Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Estriol + progesterone is a combination of two naturally occurring steroid hormones—estriol, an estrogen, and progesterone, a progestogen. This combination is used primarily in hormone replacement therapy (HRT) for postmenopausal women to treat symptoms such as atrophic vaginitis and other menopausal complaints. Estriol acts by binding to estrogen receptors and alleviating symptoms related to estrogen deficiency, while progesterone opposes the proliferative effects of estrogens on the endometrium, reducing the risk of endometrial hyperplasia. The combination may be administered intravaginally or orally; however, most FDA-approved oral HRT products use estradiol rather than estriol as the estrogen component[7][5]. Clinical studies have shown that intravaginal administration of estriol plus progesterone can improve vaginal health parameters without significant systemic absorption or increased risk of endometrial hyperplasia over six months[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on estriol + progesterone.